BOND LABORATORIES, INC. Form 10-Q November 16, 2009

> U.S. Securities and Exchange Commission Washington, D.C. 20549

FORM 10-Q

(Mark One)

x Quarterly Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

For the quarterly period ended September 30, 2009

o Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act

For the transition period from N/A to N/A

Commission File No. 333-137170

Bond Laboratories, Inc. (Name of small business issuer as specified in its charter)

Nevada State of Incorporation 20-3464383 IRS Employer Identification No.

11011 Q Street Building A Suite 106 Omaha, NE 68137 (Address of principal executive offices)

> (402) 884-1894 (Issuer's telephone number)

Securities registered under Section 12(b) of the Exchange Act:

None

Securities registered under Section 12(g) of the Exchange Act:

Common Stock, \$0.01 par value per share (Title of Class) Indicate by check mark whether the Registrant (1) has filed all reports required by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the Registrant was required to file such reports) and (2) has been subject to such filing requirements for the past 90 days:

Yes x No "

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files).

Yes "No "

Indicate by check mark whether the Registrant is a large accelerated filer, an accelerated filer, or a non–accelerated filer. See definition of "accelerated filer and large accelerated filer" in Rule 12b–2 of the Exchange Act. (Check one):

Large accelerated filer	 Accelerated filer	
Non–Accelerated filer	 Small Business Issuer	Х

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b–2 of the Exchange Act).

Yes "No x

Transitional Small Business Disclosure Format (check one): Yes o No x

Indicate the number of shares outstanding of each of the issuer's classes of common stock, as of the latest practicable date.

Class Common stock, \$0.01 par value Outstanding at November 10, 2009 53,543,304

BOND LABORATORIES, INC. INDEX TO FORM 10-Q FILING FOR THE THREE AND NINE MONTHS ENDED SEPTEMBER 30, 2009 AND 2008

TABLE OF CONTENTS

PART I FINANCIAL INFORMATION PAGE

		Page
PART I - FINANCIAL INFORMATION		
<u>Item 1.</u>	Condensed Consolidated Financial Statements	
	Condensed Consolidated Balance Sheets	1
	Condensed Consolidated Statements of Income	2
	Condensed Consolidated Statement of Cash Flows	3
	Notes to Condensed Consolidated Financial Statements	4
<u>Item 2.</u>	Management Discussion & Analysis of Financial Condition and Results of Operations	19
<u>Item 3.</u>	Quantitative and Qualitative Disclosures About Market Risk	23
<u>Item 4.</u>	Controls and Procedures	23
PART II - OTHER INFORMATION		
<u>Item 1.</u>	Legal Proceedings	24
Item 1A.	Risk Factors	24
<u>Item 2.</u>	Unregistered Sales of Equity Securities and Use of Proceeds	29
<u>Item 3.</u>	Defaults Upon Senior Securities	31
<u>Item 4.</u>	Submission of Matters to a Vote of Security Holders	31
Item 5	Other information	31
<u>Item 6.</u>	Exhibits	31

CERTIFICATIONS

Exhibit 31 – Management certification Exhibit 32 – Sarbanes-Oxley Act

-i-

Table of Contents

PART I – FINANCIAL INFORMATION

ITEM 1 – FINANCIAL STATEMENTS

BOND LABORATORIES, INC. CONDENSED CONSOLIDATED BALANCE SHEETS

ASSETS: CURRENT ASSETS	September 30, 2009 (Unaudited)	December 31, 2008 (Audited)
Cash	\$1,290,219	\$263,379
Accounts receivables - net	547,690	428,790
Inventory	2,248,917	1,984,245
Notes receivables	11,095	250,137
Prepaid expenses and other current assets	66,598	30,240
Total current assets	4,164,519	2,956,791
	005 050	220,220
PROPERTY AND EQUIPMENT, net	235,850	238,328
Intangibles assets, net	1,971,049	2,160,860
Deposits	9,510	5,728
TOTAL ASSETS	\$6,380,928	\$5,361,707
	+ •,• • • •,• = •	+ = ,= = = , : = :
LIABILITIES AND STOCKHOLDERS' EQUITY:		
CURRENT LIABILITIES:		
Accounts payable	\$767,499	\$950,947
Accrued expenses and other liabilities	143,346	238,617
Note payable - affiliate	100,000	50,769
Note payable - current	436,789	934,861
Total current liabilities	1,447,634	2,175,194
Notes payable - long term - affiliate	521,775	118,102
TOTAL LIABILITIES	1,969,409	2,293,296
CONTINGENCIES AND COMMITMENTS		
CONTINUENCIES AND COMMITMENTS	-	-
STOCKHOLDERS' EQUITY:		
Preferred stock series A, \$.01 par value, 10,000,000 shares authorized; 5,148,646		
and 5,659,477 issued and outstanding as of September 30, 2009 and December 31,		
2008, respectively	51,486	56,595
Preferred stock series B, \$.01 par value, 1,000 shares authorized; 219.3 and 0		
issued and outstanding, including accretion of liquidation preferences price		
differential of \$2,193,000, 10% Cummulative Perpetual with a Stated Value of		
\$10,000 per share and has dividend cummulated of \$164,026 as of September 30,		
2009 and December 31, 2008, respectively	607,236	-
	488,304	258,399

Edgar Filing: BOND LABORATORIES, INC. - Form 10-Q

Common stock, \$.01 par value, 75,000,000 shares authorized;48,830,404 and 25,839,928 issued and outstanding as of September 30, 2009 and December 31, 2008, respectively

Additional paid-in capital	20,211,656	12,306,023		
Common stock subscribed, 3,230,025 and 7,500,000				
as of September 30, 2009 and December 31, 2008, respectively	1,672,555	1,249,792		
Preferred A stock subscribed, 4,000,000	-	600,000		
Preferred B stock subscribed, 125	-	208		
Cost of raising capital	(616,066)	-		
Foreign translation	358	-		
Accumulated deficit	(18,004,010)	(11,402,606)		
Total stockholders' equity	4,411,519	3,068,411		